- Conditions
- Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 12
- States / cities
- Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more
Recruitment Status
Active, not recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10537
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 997–1008 of 10,537 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Laxity; Skin
- Interventions
- Matrix Pro
- Device
- Lead sponsor
- Candela Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Pirtobrutinib, Rituximab, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
- Interventions
- Visbiome, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- BMS-986446, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 119
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Petosemtamab, Pembrolizumab
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more
- Conditions
- Uterine Fibroid
- Interventions
- LIFE program
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • Portland, Oregon
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Frexalimab, Placebo, Insulin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 815
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more